NEUROSURGERY, cilt.59, sa.6, ss.1296-1302, 2006 (SCI-Expanded)
OBJECTIVE: Mitoxantrone (MTZ) has potent in vitro activity against malignant glioma cell lines, but it,cannot be used effectively as a systemic agent for the treatment of brain tumors because of its poor central nervous system penetration. However, MTZ-loaded poly(lactide-co-glycolide) (PLGA) microspheres may be injected into the peritumoral area and into tumor tissue to provide effective and sustained local drug concentrations without causing systemic side effects.